Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country save search
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
RLYB | News | $1.76 -2.22% -3.45% 470K
|
|
| O: -4.44%
H: 0.0%
C: 0.0%
pharmacy review care meeting
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
URGN | $14.24 -1.73% -1.54% 190K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
association for meeting benefits
Lipella Pharmaceuticals Expands its Advisory Board
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
LIPO | News | $0.749 -1.6% -8.59% 26K
|
|
| O: -0.96%
H: 5.56%
C: 4.17%
pharmaceuticals
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
KRMD | News | $2.12 -1.4% -1.42% 140K
|
Health Technology
|
| O: -0.94%
H: 4.29%
C: 0.95%
first report medical financial results
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 2
|
Health Technology
|
| O: -1.08%
H: 1.09%
C: -0.55%
rtu first
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $14.24 -1.73% -1.54% 190K
|
Health Technology
|
| O: 1.46%
H: 1.17%
C: -1.44%
ugn-103 fda drug bladder cancer for application
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | $4.78 -0.83% -0.84% 600K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
NRXP | News 0 d | $4.18 -2.79% -3.12% 91K
|
Manufacturing
|
| O: 1.17%
H: 0.29%
C: -5.41%
htx-100 pharmaceuticals
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
IOBT | $1.5 -0.66% 1.95% 37K
|
|
| O: 0.65%
H: 1.92%
C: -3.21%
biotech commercialization
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
SNGX | $0.51 8.05% -7.27% 4M
|
Health Technology
|
| O: 75.34%
H: 37.73%
C: -30.58%
fda drug marburg infection designation for grants
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
LEGN | $48.83 -2.57% -2.62% 1.4M
|
Health Technology
|
| O: 0.02%
H: 0.22%
C: -0.88%
first conference biotech results
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PTCT | News | $25.16 -0.51% -0.4% 670K
|
Health Technology
|
| O: 2.01%
H: 1.35%
C: -0.18%
first conference therapeutics financial results
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE A | $25.42 -1.05% 0.16% 40M
|
Health Technology
|
| O: 0.11%
H: 0.38%
C: -0.04%
meeting
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
SNGX | $0.51 8.05% -7.27% 4M
|
Health Technology
|
| O: 3.67%
H: 0.46%
C: -19.02%
fda drug infection designation for grants
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -0.83% -20.84% 34K
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.93 -0.57% -0.55% 3.8M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.8162 8.86% 9.33% 180K
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.96 -1.98% -1.76% 24K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
RLYB | News | $1.76 -2.22% -3.45% 470K
|
|
| O: -3.03%
H: 4.38%
C: 1.87%
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
risk solutions for collaboration
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
TRVI | $2.58 -3.19% -3.29% 250K
|
Health Technology
|
| O: 2.77%
H: 1.59%
C: -8.57%
conference presentation international therapeutics
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $25.42 -1.05% 0.16% 40M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
SVRA | $4.96 -3.88% -4.03% 2.1M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: -2.3%
conference international
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VIAO | $0.262 0.77% 16.03% 14M
|
Electronic Technology
DXF | $0.2708 -5.71% 14.48% 190K
|
Finance
SYTA | $2.9 17.89% 12.77% 300K
|
Non-Energy Minerals
BHIL | $0.1722 -3.8% 12.08% 290K
|
Agriculture, Forestry, Fishing ...
ANVS | $8.99 -10.81% 10.9% 270K
|
Health Technology
AUST | $1.15 -7.26% 8.7% 79K
|
n/a
ATNM | $7.25 -6.33% 8.69% 280K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.